Patients with moderate Alzheimer’s showed no benefit at all from the system, called Spectris, according to data provided by the company, Cognito Therapeutics, which sponsored the trial. But for patients with mild Alzheimer’s, data generally suggested they could experience slower decline with the device, particularly if they used it nearly every day for close to the recommended 60 minutes....
The patient whose description of the experience is in the post title said, "If I have to do it again, I won’t. I will not use it again because that hour seemed like three hours."
One of the investigators noted that some people "didn’t like having something on their face."
The article is pretty long but lacks a photograph of a person wearing the thing. The only photo is a stock photo of the back of an old man's head. I found this image myself:


32 comments:
"data generally suggested"...
I smell a potential trial replication problem.
My last long term contract job was working on clinical trials for dementia drugs for a major pharma. Focused on the amyloid plaque theory. We did have one success. Plaque dissolved. Unfortunately, no benefit to patients. My dad suffered a decade of Alzheimer’s. It’s a long story that I won’t tell here, but that experience led me to my “death by thousand cuts” theory. A lifetime of physical and psychological cuts that eventually lead to systemic breakdown.
Less creepy than those anti-aging light face masks they advertise on TV.
Each generation has its own form of snake oil.
My wife was diagnosed with early onset of Alzheimers a couple of years ago. After 18 months of infusions ($1,200 every two weeks before Medicare kicked in) of Leqembi her amyloid plaques have disappeared, at least for now.
An hour of static would have me ready to murder. How does that compare with an hour of meditation? Or an hour of orchestral music?
I googled for the price of one of these things: "The Cognito Spectris is an investigational, non-invasive neuromodulation system that does not yet have a final commercial retail price.
However, early health economic modeling presented by Cognito Therapeutics indicates that the device is projected to be cost-effective at an estimated acquisition cost ranging from $44,000 to $108,000, depending on clinical efficacy scenarios and a $100,000 willingness-to-pay threshold."
Whatever "projected to be cost-effective at an estimated acquisition cost" means, it sounds expensive.
All for the effect of a broadcast TV with no signal.
'..."The Cognito Spectris is an investigational, non-invasive neuromodulation system that does not yet have a final commercial retail price.....'
This sounds like it might be good for updating my old turbo encabulator.
One could try running a free white noise app from one's phone instead.
Billions spent on research and we are no closer to a cure since my Grandmother died of the disease in the 1980's. Since then I have witnessed friends and relatives fade away and die with it. Currently my younger brother is in hospice and my wife is in year three of her journey.
It is a money maker for researchers and quacks alike. For the rest of us we are faced with a long and sad goodbye to our loved ones.
This looks a lot like the peripheral neuropathy light stimulation that supposedly allows nerve regeneration in feet. That doesn't work either.
It seems that once the disease reaches a certain point, it cannot be reversed or stopped, only slowed. Therefore, prevention is the best option but it requires significant lifestyle changes and is still no guarantee.
My father has Parkinson's dementia. He's in and out. It's really sad. He goes to a class where they wear VR headsets. I got him his own headset but he never uses it. He can't read. He sees TV, but he still gets confused. Sees a train wreck on TV and worries that I'm going to get arrested for the train wreck. Accused me of losing $6 million in the stock market. Keeps wanting to stand up, when he can't stand up. It's stressful. None of his friends visit anymore. I go once a week. My Mom goes every day, twice a day.
On Sunday I told him, "Dad, when I was little, you were the only one in our family praying to God. Mom never prayed, I never prayed, Ted never prayed. But you were always praying to the Lord, doing your Day by Day. And that's why we had such a blessed life." And he heard me. And his eyes were happy. And he said, "You're welcome."
AA, above: "All for the effect of a broadcast TV with no signal."
Makes me think of the little girl sitting in front of the old-fashioned TV with no signal, at the start of Speilberg's horror movie, Poltergeist:
"They''re here!"
Sadly, with dementia, they're usually NOT here.
Shouting Thomas, any thoughts on whether the plaques are symptom rather than a cause? If they dissolve and disappear but the person doesn't improve - I mean, I see your point about the death by a thousand cuts, and the LAST thing I am is a medical researcher, but - when my dog was on steroids for her lymphoma and it had been almost six months since her diagnosis (and we expected her to last no more than three), she ate something dead and gross (she always loved to find gross things on our walks - I was better at keeping her away from them than my husband was). We thought, ew, gross, but because she'd always done that and didn't have any immediate effects, we thought she'd gotten away with it again. But after a couple of days, she got horrible diarrhea and wouldn't eat, both of which were also possible symptoms of the end of her steroid remission. My husband thought it was the rat she ate; I thought it was the end.
So we took her to the vet. She agreed with my husband, to my surprise, and gave her antibiotics and a probiotic to try to rebuild her gut microbiome after the course was done. And she improved - dramatically and within a day. She lasted another almost six weeks, because the diarrhea and fasting for a couple of days weren't a result of the lymphoma.
But they *were* a result of the *steroid* - its suppression og her immune system. So the things I thought were directly related to the lymphoma were actually only indirectly related. That's where I was going with this: what if amyloid plaques are only indirectly related to Alzheimer's, caused by it but not actually related to the symptoms we all know and dread? Or even not at all related - just coincidental?
I ask the same question about cholesterol and statins.
Spectris and Dr. Cognito sound like Bond villains.
So when you have Alzheimer's everything is color of television, tuned to a dead channel? Good to know. When that starts happening, I'll call the doctor and not go fumbling for the clicker.
Saint Croix, I'm sorry for what you're going through. In all seriousness, your story reminds me of a scene from "A Beautiful Day In The Neighborhood," the movie about Mr. Rogers. There's a scene where Mr. Rogers asks a terminally ill man to pray for him, because he's closer to God than anyone else.
The picture reminds me of a scene from the rock opera “Tommy.”
$100,000? GMAFB. That's a couple hundred BOM cost plus some software. If this sells at all there will be chinese knock-offs being sold at every senior center in the country, for $200.
"didn’t like having something on their face."
"No mask No service"
When I was a kid I would close my eyes and lightly push in my closed eyelids with my fingers to see a light show. It didn't cost me a thing.
It doesn't work anymore. I might be going blind.
“My dad suffered a decade of Alzheimer’s. It’s a long story that I won’t tell here, but that experience led me to my “death by thousand cuts” theory. A lifetime of physical and psychological cuts that eventually lead to systemic breakdown.”
Thank you Tom T, I appreciate it.
Pertaining to Leqembi treatment…
• Genetic Factor: Patients with two copies of the ApoE ε4 gene have a higher risk of developing serious ARIA. Pre-treatment genetic testing is recommended.
To go with my 1:20PM quote.
“How APOE4 Affects Alzheimer’s Risk
• Gene Copies: You inherit two copies of the APOE gene (one from each parent), which can result in variants like APOE2, APOE3, or APOE4.
• Single Copy (Heterozygous): Carrying one copy of APOE4 increases your risk of developing Alzheimer’s disease by roughly 2 to 3 times compared to having the common APOE3/APOE3 genotype. Lifetime risk rises to about 25%–33%.
• Two Copies (Homozygous): Carrying two copies of APOE4 increases the risk by 10 to 12 times or more, with lifetime risk estimates reaching 60%–77%. Recent research from Nature Medicine suggests that having two APOE4 copies acts with near-full penetrance for Alzheimer's biology as people age.
• Age of Onset: One copy can accelerate the onset of symptoms by 2 to 5 years, while two copies can accelerate it by 5 to 10 years.
Biological Impact
• Lipid and Cholesterol Processing: The ApoE4 protein is less efficient at clearing cholesterol and handling lipids in brain cells, leading to cellular stress and lipid droplet accumulation.
• Plaque and Inflammation: APOE4 promotes the buildup of amyloid-beta plaques and tau tangles, while encouraging brain immune cells (microglia) to shift into a damaging, inflamed state.”
Google AI
A long time family friend of ours just recently died in hospice after 10 years of “The Long Goodbye”. She was a bright, kind, wonderful woman, friend, mother and teacher. Her daughter barely made it to her bedside before she passed due to the November 13 ground stop. She was trying to fly from MN to AZ.
Sadly…
“Taking a statin has not been proven to directly prevent APOE4-related brain (beta-amyloid) plaques from forming, though observational research and clinical data on how statins affect Alzheimer’s risk in APOE4 carriers remain mixed.
The Cholesterol Connection: Blood cholesterol does not directly cross the blood-brain barrier; the brain manufactures its own cholesterol. While statins effectively manage systemic blood cholesterol and protect heart and vascular health—which indirectly supports long-term brain health—their direct impact on brain amyloid plaque deposition in APOE4 carriers is unproven.”
Google AI
Jaime…
“…any thoughts on whether the plaques are symptom rather than a cause?”
“How Plaques Damage the Brain
• Disrupting Synapses: Long before massive plaque deposits show up, smaller amyloid oligomers attack synapses (the contact points where neurons pass chemical signals to each other), cutting off neural communication.
• Triggering Inflammation: The brain treats the plaque buildup as damage, activating immune cells called microglia and astrocytes. While meant to clear debris, chronic activation of these cells triggers sustained neuroinflammation that damages surrounding healthy neurons.
• Paving the Way for Tangles: Amyloid plaque accumulation is closely linked to the spread of tau tangles—twisted protein fibers that form inside neurons, causing their internal transport tracks to collapse and leading to cell death.
• Vascular and Flow Issues: Stiff, hyper-contracted blood vessels in the brain fail to flush out metabolic waste properly, trapping amyloid and compounding oxygen and nutrient deprivation.”
Google AI
As for dementia in Parkinson’s, different reasons…
Growing old can be a bitch.
“Parkinson's disease dementia is caused by the abnormal buildup of a protein called alpha-synuclein inside brain cells, forming microscopic clumps known as Lewy bodies.
How It Develops
• Initial Brain Damage: Early in Parkinson's disease, Lewy bodies primarily target the basal ganglia and areas like the substantia nigra, damaging nerve cells (neurons) that produce dopamine and control movement”
Google AI
“ The overall results for both moderate and mild groups did not meet the statistically significant threshold that scientists consider necessary for reliable findings.”
In other words, it’s crap. If you want audiovisual stimulation, watch porn.
I asked GPT: “It’s been a long time since I worked for [X pharma] on an Alzheimer’s drug trial. Shrank the plaque, but no benefit to patient. That was now 20 years ago. Has there been any progress in a drug that reverses or delays Alzheimer’s?”
GPT: “The first approved drugs to show a disease-slowing effect are lecanemab (Leqembi) and donanemab (Kisunla). In trials, people with early Alzheimer’s—mild cognitive impairment or mild dementia, with amyloid confirmed—still declined on average, but more slowly than people given placebo. Lecanemab reduced decline by about 27% over 18 months; donanemab also reduced decline on measures of cognition and daily function over 76 weeks. Those percentages describe the difference between groups in trials: they don’t mean patients improved by that amount or stopped declining.”
“So the honest answer is: we now have drugs that can slow decline for some people when treatment begins early; we do not yet have a drug shown to restore abilities already lost or reverse Alzheimer’s. The approved drugs also require careful screening and MRI monitoring because they can cause brain swelling or bleeding, occasionally severe or fatal.”
Post a Comment
Please use the comments forum to respond to the post. Don't fight with each other. Be substantive... or interesting... or funny. Comments should go up immediately... unless you're commenting on a post older than 4 days. Then you have to wait for us to moderate you through. It's also possible to get shunted into spam by the machine. We try to keep an eye on that and release the miscaught good stuff. We do delete some comments, but not for viewpoint... for bad faith. Also: No italics, even briefly. Use asterisks for emphasis. And don't play with the format by changing fonts or using boldface or all caps. Never include more than one extra line break between paragraphs.